febit Receives European Union Patent for Synthesis of Minimal Genomes
News Apr 26, 2010
febit announced the receipt of an EU patent, #EP 1 728 860B1, for its technology to synthesize minimal genomes.
The new patent protects febit’s technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis of oligonucleotides for gene-assembling.
A minimal genome contains only the genetic information which is required to sustain life of a certain organism under predefined conditions. Minimal genomes help to identify essential genes and investigate the isolated activity of interesting genes in minimal cells. The synthesis of minimal genomes complements febit’s portfolio which contains groundbreaking technologies for the exploration of the genome. HybSelect, for example, is a technology for the enrichment of interesting genes for targeted resequencing. febit’s miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE